OncoSec Medical Stock

OncoSec Medical EBIT per Share

Delisted

EBIT per Share of OncoSec Medical (ONCS) as of Aug 11, 2026.

EBIT per Share

0.00USD

Last updated:

EBIT per Share of OncoSec Medical is 2026 0.00 USD. EBIT per Share of OncoSec Medical was 2025 0.00 USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

OncoSec Medical Stock analysis

What does OncoSec Medical do? OncoSec Medical Inc is a US-based company specializing in the development of cancer treatment methods through immunotherapy. The company was founded in 2011 and is headquartered in San Diego, California. The history of OncoSec Medical Inc began with the idea of improving tumor treatments through electroporation. Electroporation is a process that uses electric pulses to increase the permeability of cell membranes. This facilitates the exchange of molecules and the uptake of drugs, which is used in the treatment of cancer cells. The business model of OncoSec Medical Inc is based on the development and commercialization of immunotherapies to combat cancer. Electroporation is used to locally infect tumor lesions with reactivated T-cells and other immune cells to generate an immune response. OncoSec Medical Inc has developed a proprietary platform called ImmunoPulse, which combines electroporation and immunotherapy. The company is divided into various divisions, including research and development, clinical trials, manufacturing, and distribution. Research and development focus on identifying potential immunotherapies and testing drug candidates. Clinical trials are designed to confirm the effectiveness and safety of therapies through clinical testing. Manufacturing involves the production of drug candidates and clinical preparations in accordance with Good Manufacturing Practices (GMPs). Distribution includes the sale and marketing of approved therapies to patients and healthcare providers. OncoSec Medical Inc offers a variety of immunotherapies for the treatment of various types of cancer. This includes ImmunoPulse IL-12 therapy, which is used to treat metastatic melanoma. The company is also working on several other therapies, including the Verapamil-Plus-IL-2 protocol for the treatment of breast and prostate cancer. In summary, OncoSec Medical Inc is an emerging biotechnology company specializing in the development and commercialization of immunotherapies to combat cancer. Through its proprietary ImmunoPulse platform and extensive research and development, the company strives to provide effective and safe treatment options for cancer patients, fully harnessing the potential of immunotherapy. OncoSec Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OncoSec Medical stock

On Eulerpool you can find the complete historical development of EBIT per Share OncoSec Medical since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

Income Statement — OncoSec Medical

All Key Metrics — OncoSec Medical